TW202345803A - 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 - Google Patents

由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 Download PDF

Info

Publication number
TW202345803A
TW202345803A TW112108996A TW112108996A TW202345803A TW 202345803 A TW202345803 A TW 202345803A TW 112108996 A TW112108996 A TW 112108996A TW 112108996 A TW112108996 A TW 112108996A TW 202345803 A TW202345803 A TW 202345803A
Authority
TW
Taiwan
Prior art keywords
insert
eye
day
days
pva
Prior art date
Application number
TW112108996A
Other languages
English (en)
Chinese (zh)
Inventor
賽德 薩姆
杰 Ｓ 杜克
達里歐 帕格吉亞里諾
Original Assignee
美商視點製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商視點製藥有限公司 filed Critical 美商視點製藥有限公司
Publication of TW202345803A publication Critical patent/TW202345803A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW112108996A 2022-03-11 2023-03-10 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 TW202345803A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263318822P 2022-03-11 2022-03-11
US63/318,822 2022-03-11
US202263390036P 2022-07-18 2022-07-18
US63/390,036 2022-07-18

Publications (1)

Publication Number Publication Date
TW202345803A true TW202345803A (zh) 2023-12-01

Family

ID=85873993

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112108996A TW202345803A (zh) 2022-03-11 2023-03-10 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法

Country Status (9)

Country Link
US (1) US20250205152A1 (https=)
EP (1) EP4489749A1 (https=)
JP (1) JP2025508127A (https=)
KR (1) KR20250002220A (https=)
AU (1) AU2023230975A1 (https=)
CA (1) CA3245205A1 (https=)
IL (1) IL315331A (https=)
TW (1) TW202345803A (https=)
WO (1) WO2023173088A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
WO2018059556A1 (zh) 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
EP4537830A3 (en) * 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
AU2021340733A1 (en) * 2020-09-14 2023-05-18 EyePoint Pharmaceuticals, Inc. Bioerodible ocular drug delivery insert and therapeutic method

Also Published As

Publication number Publication date
US20250205152A1 (en) 2025-06-26
IL315331A (en) 2024-10-01
WO2023173088A1 (en) 2023-09-14
CA3245205A1 (en) 2023-09-14
AU2023230975A1 (en) 2024-09-19
JP2025508127A (ja) 2025-03-21
EP4489749A1 (en) 2025-01-15
KR20250002220A (ko) 2025-01-07

Similar Documents

Publication Publication Date Title
US12551368B2 (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
CA3171479A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
TW202345803A (zh) 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
US20250186336A1 (en) Method of treating wet age-related macular degeneration
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118700A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
HK40118703A (zh) 治疗湿性年龄相关性黄斑变性的方法
HK40118701A (zh) 用於治疗眼睛病症的持续给药方案
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method